In this regard, several GLUT inhibitors have been evaluated for their benefits in HCC treatment; however, mainly GLUT1 has been targeted, as it is generally overexpressed in cancer [54–56]. The gene discussed is SLC2A1; the disease is hepatocellular carcinoma.